Robust therapeutic effects of CAR-T-cells in mice bearing U87-EGFRvIII tumors. (A) Schematic of the experimental protocol. NSG mice received i.c. inoculation of 5×104 U87-EGFRvIII-Luc cells on day -7 and subsequently received a single i.v. infusion of 2×106 T cells transduced with pELNS-3C10-CAR alone or with both pELNS-3C10-CAR and FG12-EF1a-miR-17/92 or mock vector on day 0. All mice received i.p. administration of TMZ (0.33 mg/mouse/day) on days 0–4. (B) Kaplan-Meier analysis. Median survival of the mice treated with CAR-T cells (with or without co-transduction of miR-17-92; n = 10/group) was significantly greater compared with the mice treated with mock-transduced T cells (p < 0.05). All mock-transduced mice (n = 5) died by day 21. (C) Longitudinal measurements of tumor-derived mean photon flux ± SD. The background luminescence level (up to 103 p/s) was defined based on the levels observed in non-tumor-bearing mice imaged in parallel with the tumor-bearing mice. Results are from one of two independent experiments with similar results.